Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. [electronic resource]
Producer: 20120328Description: 598-609 p. digitalISSN:- 1555-8576
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Bridged Bicyclo Compounds, Heterocyclic -- administration & dosage
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cyclic N-Oxides
- Cyclin-Dependent Kinases -- antagonists & inhibitors
- Deoxycytidine -- administration & dosage
- Drug Resistance, Neoplasm -- genetics
- Enzyme Inhibitors -- pharmacology
- Humans
- Indolizines
- Male
- Mice
- Mice, Nude
- Pancreatic Neoplasms -- drug therapy
- Phosphorylation -- drug effects
- Pyridinium Compounds -- administration & dosage
- Receptors, Notch -- genetics
- Retinoblastoma Protein -- metabolism
- Signal Transduction
- Transforming Growth Factor beta -- metabolism
- Xenograft Model Antitumor Assays
- ral GTP-Binding Proteins -- metabolism
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.